01—Abstract
Summary
Summary of the 8-K filed March 23, 2026. Cited figures are marked; the original filing is the authoritative source.
Cardinal Health (NYSE: CAH) filed an 8-K on March 23, 2026 disclosing a board leadership change and a reaffirmed outlook.
Gregory B. Kenny, who had served on the Board since 2007 and as Chair since 2018, retired from the Board, all committees, and his Chair role effective March 20, 2026. The filing states the retirement was not the result of any disagreement with the Company on its operations, policies, or practices.
The Board immediately appointed Patricia A. Hemingway Hall, a current director since 2013 and former chair of the Governance and Sustainability Committee, as Board Chair. For investors, this is primarily a governance transition rather than a financial event.
Hemingway Hall brings institutional knowledge of Cardinal's strategy and governance framework, along with healthcare leadership experience as former CEO of Health Care Service Corporation. Because she is already an insider, the change is likely to produce continuity rather than a strategic reset. The filing contains no financial results, no changes to guidance, and no new compensation terms.
The company also reaffirmed its fiscal 2026 outlook and said it will release third quarter fiscal 2026 earnings on April 30, 2026. That date is the next concrete catalyst for investors to reassess the outlook. The forward-looking statements flag ongoing risks, including pharmaceutical pricing and tariff regulation, the GMPD Improvement Plan, generic deflation, and a Department of Justice investigation into potential Anti-Kickback Statute and False Claims Act violations.
02—Key points
Key Highlights
- Gregory B. Kenny retired from the Board, all committees, and his role as Board Chair, effective March 20, 2026, after notifying the company on March 17, 2026.
- The company states Kenny's retirement was not due to any disagreement with management on operations, policies, or practices.
- Patricia A. Hemingway Hall, a director since 2013, was immediately appointed Board Chair; she previously chaired the Governance and Sustainability Committee for nearly seven years.
- Hemingway Hall is the former President and CEO of Health Care Service Corporation, the nation's largest mutual health insurer.
- Cardinal Health reaffirmed its fiscal 2026 outlook and will release third quarter fiscal 2026 earnings on April 30, 2026.
- The filing contains no financial results, guidance changes, or new compensation arrangements.
- Forward-looking risks flagged include pharmaceutical pricing and tariff regulation, the GMPD Improvement Plan, generic deflation, and a DOJ investigation into Anti-Kickback Statute and False Claims Act matters.
03—Questions
Frequently Asked Questions
Why did Gregory Kenny step down as Board Chair?
The 8-K states Kenny chose to retire from the Board, all committees, and his Chair role, and that the decision was not the result of any disagreement with the company on operations, policies, or practices. No further personal reasons were disclosed.
Who is replacing Kenny, and how qualified are they?
Patricia A. Hemingway Hall, an existing director since 2013, was appointed Board Chair effective immediately. She chaired the Governance and Sustainability Committee for nearly seven years and previously served as CEO of Health Care Service Corporation, giving her both governance and healthcare industry experience.
Does this leadership change affect Cardinal Health's financial outlook?
The filing does not indicate any change to financial outlook. Management reaffirmed its fiscal 2026 outlook in the same announcement, and the board change is not expected to alter operations on its own.
When should investors expect the next update?
Cardinal Health plans to release third quarter fiscal 2026 earnings on April 30, 2026. That report will be the first major opportunity to test whether the reaffirmed fiscal 2026 outlook still holds.
Are there outstanding legal or regulatory risks investors should monitor?
Yes. The forward-looking statements cite a Department of Justice investigation into potential Anti-Kickback Statute and False Claims Act violations, along with pharmaceutical pricing and tariff regulation, generic deflation, and execution of the GMPD Improvement Plan. The filing does not quantify these risks.
04—Continue